News Sentiment

AVIR sentiment intelligence

Atea Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 52 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.99 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

80/100 classification confidence.

Company focus 44

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

+0.2% over one week, +11.1% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

Atea Pharmaceuticals Begins Phase 1 Clinical Trial of Potential Hepatitis E Treatment

Market Reaction

Balanced read

52/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 80/100 classification
One-week reaction 0.2% Price digesting
Trend fit Trend inactive 11.1% over four weeks
Fair value 38.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 10
Neutral 40
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 44
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 9
Market source 8
TradingView 8
Quartr 5
simplywall.st 4
GlobeNewswire 3
MT Newswires 2
Finviz 2

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 21
Analyst action 2
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 52
Yahoo! Finance Canada Direct company coverage

Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus

Atea Pharmaceuticals has initiated a Phase 1 clinical trial for AT-587, a potential first-in-class oral antiviral nucleotide analog for Hepatitis E Virus (HEV). This study will assess the safety, tolerability, and pharmacokinetics of AT-587 in healthy volunteers, aiming to addres

Tone
Positive 75/100
Event
Market update
Published
14 Jul 2026 10:42
Source
Yahoo! Finance Canada
Stock Titan Direct company coverage

Hepatitis E Has No Approved Treatments as Atea Begins Human Trial

Atea Pharmaceuticals (NASDAQ: AVIR) has initiated a Phase 1 clinical trial for AT-587, an oral nucleotide analog aimed at treating hepatitis E virus (HEV), a serious liver disease with no approved treatments. Preclinical studies showed that AT-587 is 30-150 times more potent than

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 10:42
Source
Stock Titan
Quartr Direct company coverage

Atea Pharmaceuticals (AVIR) Proxy filing Summary

Atea Pharmaceuticals (AVIR) has filed a proxy summary detailing its upcoming annual meeting on June 18, 2026. Key agenda items include the election of three Class III directors, ratification of KPMG LLP as the independent auditor, and an advisory vote on executive compensation. T

Tone
Positive 63/100
Event
Market update
Published
11 Jul 2026 00:40
Source
Quartr
Quartr Direct company coverage

Atea Pharmaceuticals (AVIR) Q4 2025 earnings summary

Atea Pharmaceuticals reported its Q4 2025 earnings, highlighting an advanced global Phase III HCV program with topline results from C-BEYOND expected in mid-2026 and C-FORWARD by year-end 2026. The company also expanded its antiviral pipeline with an HEV program, expecting first-

Tone
Positive 63/100
Event
Earnings
Published
11 Jul 2026 00:40
Source
Quartr
Quartr Direct company coverage

Atea Pharmaceuticals (AVIR) Q2 2024 earnings summary

Atea Pharmaceuticals reported its Q2 2024 earnings, highlighting full enrollment in its Phase 3 SUNRISE-3 COVID-19 and Phase 2 HCV trials, with topline results expected in the second half of 2024. The company's cash position was $502.2 million as of June 30, 2024, projected to fu

Tone
Neutral 50/100
Event
Earnings
Published
11 Jul 2026 00:40
Source
Quartr
Quartr Direct company coverage

Atea Pharmaceuticals (AVIR) 7th Annual Evercore ISI HealthCONx Healthcare Conference summary

Atea Pharmaceuticals (AVIR) presented key clinical data from its Phase 2 trials for bemnifosbuvir and ruzasvir in HCV at the 7th Annual Evercore ISI HealthCONx Healthcare Conference. The company reported 98% SVR12 in adherent patients and favorable safety, with plans for an end-o

Tone
Positive 74/100
Event
Market update
Published
10 Jul 2026 16:10
Source
Quartr
Quartr Direct company coverage

Atea Pharmaceuticals (AVIR) Q1 2026 earnings summary

Atea Pharmaceuticals reported its Q1 2026 earnings, detailing progress on two pivotal Phase 3 HCV trials (C-BEYOND and C-FORWARD) with topline results expected mid-2026 and year-end 2026, respectively, and a Q1 2027 NDA submission target. The company also expanded its antiviral p

Tone
Positive 62/100
Event
Earnings
Published
10 Jul 2026 15:39
Source
Quartr
Finviz Direct company coverage

AVIR - Atea Pharmaceuticals Inc Short Interest

This article provides a detailed financial snapshot of Atea Pharmaceuticals Inc (AVIR), focusing on its short interest, key financial metrics, stock performance, and insider/institutional ownership. It includes information such as market capitalization, income, sales, price-to-bo

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 19:41
Source
Finviz
Finviz Direct company coverage

AVIR - Atea Pharmaceuticals Inc Volatility & Greeks

This article provides a detailed financial overview of Atea Pharmaceuticals Inc (AVIR), including its stock performance, volatility, key financial ratios, and insider/institutional ownership. It highlights various metrics such as market capitalization, P/E ratio, sales, EPS growt

Tone
Neutral 50/100
Event
Earnings
Published
01 Jul 2026 22:39
Source
Finviz
TradingView Direct company coverage

Price to earnings forward of Atea Pharmaceuticals, Inc. – NASDAQ:AVIR

This article provides financial information for Atea Pharmaceuticals, Inc. (NASDAQ: AVIR), focusing on its forward price-to-earnings ratio. It indicates that the market is currently closed with no trades. The content offers a brief financial overview within the TradingView platfo

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 05:39
Source
TradingView
TradingView Direct company coverage

Price to book forward of Atea Pharmaceuticals, Inc. – NASDAQ:AVIR

This article focuses on the "Price to book forward" metric for Atea Pharmaceuticals, Inc., traded on NASDAQ under the symbol AVIR. It appears to be a financial data page from TradingView, providing an overview of the company's financial information within that platform. The conte

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 21:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Atea Pharmaceuticals, Inc. – BOATS:AVIR

This article provides the enterprise value to EBITDA forward for Atea Pharmaceuticals, Inc. (AVIR) as part of the Blue Ocean Alternative Trade System (BOATS) on TradingView. It appears to be a financial data point without further analysis or context on its significance.

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 09:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Atea Pharmaceuticals, Inc. – NASDAQ:AVIR

This article provides a financial snapshot for Atea Pharmaceuticals, Inc. (NASDAQ: AVIR), focusing on its enterprise value to revenue forward. It appears to be a stub or a data point from a larger financial platform, indicating a value change and percentage change for a specific

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 06:09
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Atea Pharmaceuticals, Inc. – BOATS:AVIR

This article displays the "Price to earnings forward" information for Atea Pharmaceuticals, Inc. (BOATS:AVIR) on the TradingView platform. It shows the company's ticker symbol, market status, and available financial data sections. The content prominently features the company name

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 22:41
Source
TradingView
TradingView Direct company coverage

Atea Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:AVIR)

This article provides an overview of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) stock performance, financial estimates, and analyst forecasts. It covers key metrics such as current stock price, market capitalization, historical highs and lows, earnings details, and future revenue

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 19:37
Source
TradingView
TradingView Direct company coverage

AVIR Forecast — Price Target — Prediction for 2027

This article provides a forecast for Atea Pharmaceuticals, Inc. (AVIR) stock, including current price, historical performance, analyst price targets, and future earnings estimates. Analysts predict AVIR's price could range from $6.00 to $10.00, with earnings expected on August 6,

Tone
Neutral 50/100
Event
Analyst action
Published
26 Jun 2026 01:40
Source
TradingView
GlobeNewswire Direct company coverage

Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Atea Pharmaceuticals announced the completion of patient enrollment in its Phase 3 C-FORWARD clinical trial, evaluating bemnifosbuvir and ruzasvir (BEM/RZR) for Hepatitis C virus (HCV) treatment outside North America. The trial enrolled over 880 treatment-naïve patients across 17

Tone
Positive 73/100
Event
Market update
Published
25 Jun 2026 11:11
Source
GlobeNewswire
Stock Titan Direct company coverage

Atea Pharmaceuticals (NASDAQ: AVIR) director reports RSU exercise and new option, RSU grants

Atea Pharmaceuticals director Jerome M. Adams exercised 29,600 restricted stock units (RSUs) into common stock and received new grants of 37,700 stock options and 26,700 RSUs. These transactions are described as routine equity compensation, converting previously awarded equity in

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

Atea Pharmaceuticals (AVIR) director reports RSU vesting and new option grant

Atea Pharmaceuticals director Polly A. Murphy reported equity compensation, including the exercise of 29,600 Restricted Stock Units (RSUs) into common stock, bringing her total direct holdings to 121,745 shares. She also received a new grant of 37,700 stock options with an exerci

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

Atea (NASDAQ: AVIR) grants Bruno Lucidi options and new RSUs

Atea Pharmaceuticals director Bruno Lucidi engaged in equity compensation activities, exercising 29,600 restricted stock units into Common Stock, leading to a direct holding of 142,350 Common shares. He also received 37,700 stock options with a $4.36 exercise price and 26,700 new

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 08:10
Source
Stock Titan
Stock Titan Direct company coverage

AVIR SEC Filings - Atea Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms

This page provides a comprehensive resource for Atea Pharmaceuticals (AVIR) SEC filings, including annual reports, quarterly earnings, material events, and insider trading forms. It highlights a recent Form 3 filing on June 24, 2025, and summarizes the results of the company's Ju

Tone
Neutral 50/100
Event
Earnings
Published
24 Jun 2026 08:10
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Form 4 Atea Pharmaceuticals Inc For: 23 June By Investing.com

This article reports on a Form 4 filing for Atea Pharmaceuticals Inc. for June 23, 2026. Form 4 filings are used to report changes in beneficial ownership of a company's securities by insiders. The article notes Atea Pharmaceuticals' stock symbol as AVIR and its recent performanc

Tone
Negative 42/100
Event
Market update
Published
24 Jun 2026 06:40
Source
Investing.com Nigeria
Stock Titan Direct company coverage

[Form 4] Atea Pharmaceuticals, Inc. Insider Trading Activity

Franklin M. Berger, a director at Atea Pharmaceuticals, Inc. (AVIR), increased his equity exposure through several transactions on June 18, 2026. These included the conversion of 29,600 restricted stock units into common shares, receipt of a stock option for 37,700 shares, and a

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 00:41
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Atea Pharmaceuticals elects directors and approves proposals at annual meeting

Atea Pharmaceuticals (NASDAQ:AVIR) held its 2026 Annual Meeting of Stockholders, electing three Class III directors and approving all proposals, including the ratification of KPMG LLP as the independent public accounting firm and an advisory vote on executive compensation. The co

Tone
Positive 66/100
Event
Market update
Published
23 Jun 2026 23:40
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Director Howard Berman receives new equity awards at Atea (NASDAQ: AVIR)

Atea Pharmaceuticals director Howard Berman was granted new equity awards, including stock options for 37,700 shares at an exercise price of $4.36 and 26,700 restricted stock units. These awards, detailed in a Form 4 SEC filing, are part of his compensation and are subject to ves

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 20:41
Source
Stock Titan
Stock Titan Direct company coverage

Atea Pharmaceuticals (NASDAQ: AVIR) grants options and RSUs to director

Atea Pharmaceuticals director Arthur S. Kirsch has been granted 37,700 stock options with an exercise price of $4.36 per share, vesting monthly between June 2026 and June 2027. He also received 26,700 restricted stock units (RSUs), which will vest in a single installment by June

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 20:41
Source
Stock Titan